Serum Uric AcidNCT07091526
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
An observational study of Serum Uric Acid, run by Hepatopancreatobiliary Surgery Institute of Gansu Province at 1 site in China.
Trial summary
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Serum Uric Acid
- What is being tested?
- serum uric acid test
- How many people
- 168 participants
- Where
- 1 siteChina
- Study dates
- 29 Jul 2025to 29 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Radical pancreatic cancer resection patients
Who may be able to join
- Patients with pathologically confirmed pancreatic cancer (primary)
- Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
- The postoperative survival time was at least 6 weeks
Who cannot join
- No surgery was performed, or only palliative surgery/ biopsy was performed
- Patients who underwent emergency hemodialysis or plasma exchange after surgery
- History of gout or long-term urate-lowering therapy, such as allopurinol
- Patients are missing follow-up data
- Hydrochlorothiazide and furosemide were used
- Chronic kidney disease
Show all 14Show fewer
- Oncolytic syndrome
- Hemolytic anemia
- Lead poisoning
- Hyperparathyroidism
- Hypothyroidism
- A tyrosinase inhibitor was used
- Patients with nonpancreatic primary tumors
- Pregnant or postpartum women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Hepatopancreatobiliary Surgery Institute of Gansu Province
Lanzhou, Gansu, 730000
Wenbo Meng, MD,PhD, +8613919177177, mengwb@lzu.edu.cn
About this study
Official title: Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Read the detailed description
Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.
- Conditions
- Serum Uric Acid
- Being tested
- serum uric acid test
- Keywords
- Serum uric acid, Pancreatic cancer, Pancreaticoduodenectomy, Distal pancreatectomy
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
serum uric acid testDiagnostic test
Detect the serum uric acid in blood sample
| Study group | Role | What they receive |
|---|---|---|
| High serum uric acid | The increase of after serum uric acid operation compared with that before operation is≥10% Normal levels serum uric acid are typically 178 to 360 μm (3 to 6.8 mg/dl). Receives: Diagnostic Test: serum uric acid test | |
| Low serum uric acid | The increase of after serum uric acid operation compared with that before operation < 10% Normal serum uric acid levels are typically 178 to 360 μm (3 to 6.8 mg/dl). Receives: Diagnostic Test: serum uric acid test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Overall survival was defined as the time from diagnosis to death.
Measured: 3-5 years
Secondary outcomes (7)
Recurrence-free survival
Recurrence-free survival is the length of time from either the date of diagnosis or the start of therapy for a disease to the date of the first loco-regional or systemic recurrence.
Measured: 3-5 years
Cost of hospitalization
The cost of the first hospitalization from admission to discharge.
Measured: 3 months
Length of hospital stay
The first day of hospitalization for the first admission to the last day of discharge.
Measured: 3 months
Pancreatic fistula
Whether or not pancreatic-intestinal anastomotic leakage occurred at the time of the first hospitalization.
Measured: 3 months
Biliary fistula
Whether or not a biliary-intestinal anastomotic leak occurred at the time of the first hospitalization.
Measured: 3 months
Bleeding
Whether or not there was bleeding after the first inpatient surgery.
Measured: 3 months
Abdominal cavity infection
Whether or not there was an abdominal infection after the first inpatient surgery.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2025
- Study start29 Jul 2025
- Primary completion29 Dec 2026 (estimated)
- Study completion29 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Serum Uric AcidStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 168 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wenbo Meng, Hepatopancreatobiliary Surgery Institute of Gansu Province
- Investigators
- Wenbo Meng, M.D. Ph. D., Principal investigator, Hepatopancreatobiliary Surgery Institute of Gansu Province
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07091526
- Sponsor's protocol ID
- SUA-PC
- Status last verified
- Dec 2025
- First submitted
- 21 Jul 2025
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020 Nov 28;26(44):7061-7075. doi: 10.3748/wjg.v26.i44.7061.
PubMed 33311950Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15;1(1):16. doi: 10.1186/2001-1326-1-16.
PubMed 23369448
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
- ClinicalTrials.gov ID
- NCT07091526
- Acronym / sponsor ID
- SUA-PC
- Conditions
- Serum Uric Acid
- Keywords
- Serum uric acid, Pancreatic cancer, Pancreaticoduodenectomy, Distal pancreatectomy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 168 participants (estimated)
- Lead sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu ProvinceUniversity, hospital or other
- Study start
- 29 Jul 2025 (actual)
- Primary completion
- 29 Dec 2026 (estimated)
- Study completion
- 29 Dec 2026 (estimated)
- First posted
- 29 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Detailed description
Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High serum uric acid | – | Diagnostic Test: serum uric acid testThe increase of after serum uric acid operation compared with that before operation is≥10% Normal levels serum uric acid are typically 178 to 360 μm (3 to 6.8 mg/dl). |
| Low serum uric acid | – | Diagnostic Test: serum uric acid testThe increase of after serum uric acid operation compared with that before operation < 10% Normal serum uric acid levels are typically 178 to 360 μm (3 to 6.8 mg/dl). |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Radical pancreatic cancer resection patients
Key inclusion criteria (3 listed)
- Patients with pathologically confirmed pancreatic cancer (primary)
- Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
- The postoperative survival time was at least 6 weeks
Key exclusion criteria (14 listed)
- No surgery was performed, or only palliative surgery/ biopsy was performed
- Patients who underwent emergency hemodialysis or plasma exchange after surgery
- History of gout or long-term urate-lowering therapy, such as allopurinol
- Patients are missing follow-up data
- Hydrochlorothiazide and furosemide were used
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| serum uric acid testDetect the serum uric acid in blood sample | Diagnostic test | High serum uric acid, Low serum uric acid |
Primary outcome
Overall survival
Time frame: 3-5 years
Overall survival was defined as the time from diagnosis to death.
7 secondary outcomes
Recurrence-free survival
Time frame: 3-5 years
Cost of hospitalization
Time frame: 3 months
Length of hospital stay
Time frame: 3 months
Pancreatic fistula
Time frame: 3 months
Biliary fistula
Time frame: 3 months
Bleeding
Time frame: 3 months
Abdominal cavity infection
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Background: PubMed 33311950Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020 Nov 28;26(44):7061-7075. doi: 10.3748/wjg.v26.i44.7061.
- Background: PubMed 23369448Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15;1(1):16. doi: 10.1186/2001-1326-1-16.
- Individual participant dataSharing planned: No
Related trials for Serum Uric Acid
RecruitingPhase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Active, not recruiting
Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With Hyperuricemia
Hyperuricemia, Renal Insufficiency, Chronic
Recruiting
The Effects of Endotracheal Suctioning on Pain and Serum Markers
Intensive Care Unit ICU, Intubation
Not yet recruiting
Probiotic-Uricase Complex Preparation for Improving Uric Acid Metabolism in Patients With Hyperuricemia
Hyperuricemia, Gout
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wenbo Meng, M.D. Ph. D. principal investigator
Hepatopancreatobiliary Surgery Institute of Gansu Province
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Serum Uric Acid, run by Hepatopancreatobiliary Surgery Institute of Gansu Province at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wenbo Meng, M.D. Ph. D. (13919177177, mengwb@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 3-5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07091526, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.